Rhythm Pharmaceuticals, Inc.
RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) dā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$100.30
Price+1.84%
$1.81
1Y
Price
Market Cap
$6.694b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-82.7%
EBITDA Margin-96.1%
Net Profit Margin-48.1%
Free Cash Flow MarginRevenue
$156.287m
+20.1%
1y CAGR+105.2%
3y CAGR+241.3%
5y CAGREarnings
-$183.063m
+29.8%
1y CAGR-4.4%
3y CAGR-43.4%
5y CAGREPS
-$2.99
+29.0%
1y CAGR+2.1%
3y CAGR-37.5%
5y CAGRBook Value
$133.583m
$372.733m
Assets$239.150m
Liabilities$4.191m
DebtDebt to Assets
1.1%
-
Debt to EBITDAFree Cash Flow
-$67.724m
+40.5%
1y CAGR+26.8%
3y CAGR+15.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company